Ipsen Share Price

Equities

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris 16:35:19 30/05/2024 BST After market 18:01:57
119.4 EUR +0.51% Intraday chart for Ipsen 119.6 +0.17%

Financials

Sales 2024 * 3.47B 3.76B 295B Sales 2025 * 3.71B 4.02B 315B Capitalization 9.91B 10.75B 843B
Net income 2024 * 648M 702M 55.14B Net income 2025 * 721M 782M 61.35B EV / Sales 2024 * 2.7 x
Net cash position 2024 * 545M 590M 46.35B Net cash position 2025 * 1.19B 1.29B 101B EV / Sales 2025 * 2.35 x
P/E ratio 2024 *
15.4 x
P/E ratio 2025 *
13.9 x
Employees 5,325
Yield 2024 *
1.02%
Yield 2025 *
1.01%
Free-Float 41.59%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.51%
1 week-3.40%
Current month+4.65%
1 month+4.65%
3 months+17.64%
6 months+15.36%
Current year+10.66%
More quotes
1 week
118.00
Extreme 118
123.60
1 month
113.60
Extreme 113.6
124.50
Current year
99.70
Extreme 99.7
124.50
1 year
99.70
Extreme 99.7
130.70
3 years
77.00
Extreme 77
130.70
5 years
34.20
Extreme 34.2
130.70
10 years
31.50
Extreme 31.5
155.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 30/06/20
Director of Finance/CFO 55 02/11/14
Chairman 66 21/11/10
Members of the board TitleAgeSince
Director/Board Member 66 06/06/17
Director/Board Member 61 20/01/22
Director/Board Member 65 26/05/15
More insiders
Date Price Change Volume
30/05/24 119.4 +0.51% 51 647
29/05/24 120 +0.50% 69,870
28/05/24 119.4 -1.57% 85,313
27/05/24 121.3 -1.70% 50,046
24/05/24 123.4 -0.16% 74,948

Real-time Euronext Paris, May 30, 2024 at 04:35 pm

More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
120 EUR
Average target price
126.4 EUR
Spread / Average Target
+5.33%
Consensus